INTRODUCTION
NMDA receptors are ionotropic glutamate receptors that are critically involved in many processes in the central nervous system (CNS), including neuronal development, memory, and learning (Traynelis et al., 2010) . However, they are also implicated in a multitude of psychiatric and neurological disorders, such as schizophrenia, depression, epilepsy, stroke, and traumatic brain injury, as well as Parkinson's, Huntington's, and Alzheimer's diseases (Paoletti et al., 2013; Traynelis et al., 2010) . NMDA receptors are therefore widely considered as important targets for therapeutic intervention in many diseases of the CNS.
Seven NMDA receptor subunits have been cloned: GluN1, GluN2A-D, and GluN3A-B. The majority of native NMDA receptors are tetrameric assemblies of two GluN1 subunits and two GluN2 subunits (Traynelis et al., 2010) . GluN3 can also assemble with GluN1 and GluN2, but the stoichiometry of GluN3-containing receptors is unknown. Studies on recombinant NMDA receptors almost exclusively describe diheteromeric receptors that are assembled from GluN1 and only one type of GluN2. However, at least two different GluN2 subunits have been identified in most, if not all, NMDA receptor-expressing cells. Furthermore, a compelling body of evidence shows that a large proportion of native NMDA receptors are triheteromers assembled from two GluN1 and two different GluN2 subunits. In particular, it has been demonstrated that GluN1/GluN2A/GluN2B triheteromers account for >50% of the total NMDA receptors in hippocampus and cortex of the adult rodent brain (Al-Hallaq et al., 2007; Luo et al., 1997; Rauner and Kö hr, 2011; Sheng et al., 1994; Tovar et al., 2013 ; but see also Chazot and Stephenson, 1997) . Despite the prevalence of triheteromeric NMDA receptors in vivo, there is a fundamental gap in our knowledge of their function and pharmacology because of our inability to faithfully express these triheteromeric receptors in heterologous expression systems without accompanying diheteromeric receptors (Chazot et al., 1994; Hatton and Paoletti, 2005; Tovar and Westbrook, 1999; Vicini et al., 1998) .
Coexpression of GluN1 with two different GluN2 subunits (e.g., GluN2A and GluN2B) in heterologous systems generates three populations of functional NMDA receptors consisting of two different diheteromeric receptors (e.g., GluN1/GluN2A and GluN1/GluN2B), as well as triheteromeric receptors (e.g., GluN1/GluN2A/GluN2B). Expression of three receptor populations confounds studies on the properties of triheteromeric receptors. To mitigate this problem, we exploited the trafficking control system of the G protein-coupled GABA B receptors that are heterodimers composed of GABA B1 and GABA B2 subunits (Bettler et al., 2004) . The GABA B1 subunit possesses a retention signal (RXR motif) in the intracellular C-terminal domain (CTD) that retains the subunit in the endoplasmic reticulum (ER) and thus prevents expression of homomeric GABA B1 at the cell surface (Margeta-Mitrovic et al., 2000) . However, the retention signal is masked through a coiled-coil interaction with GABA B2 between leucine zipper motifs within in the CTDs, allowing trafficking of the heterodimer to the cell surface (Margeta-Mitrovic et al., 2000) . With some modifications, the GABA B receptor trafficking system has been utilized to express heterodimeric metabotropic glutamate receptors in heterologous systems upon transfer of the intracellular GABA B subunit CTDs (Kniazeff et al., 2004) .
We took advantage of the GABA B receptor leucine zipper motifs and engineered C-terminal peptide tags that were used to selectively express recombinant triheteromeric receptors at the cell-surface without confounding coexpression of diheteromeric receptors. Thus, this approach enables quantitative evaluation of functional and pharmacological properties of GluN1/ GluN2A/GluN2B triheteromeric receptors.
RESULTS
Selective Cell-Surface Expression of Triheteromeric GluN1/GluN2A/GluN2B Receptors In order to selectively express triheteromeric NMDA receptors at the cell surface, we engineered two different C-terminal peptide tags composed of the leucine zipper motifs from GABA B1 and GABA B2 (LZ1 and LZ2, respectively) immediately followed by C-terminal dilysine KKXX ER retention/retrieval motifs ( Figure 1A ; Figure S1 available online). The leucine zipper motifs of GABA B1 and GABA B2 can interact to form a parallel heterodimeric coiledcoil structure (Kammerer et al., 1999) . The KKXX motifs at the distal C termini will localize the subunits in the endoplasmic reticulum (ER) (Zerangue et al., 2001 ) unless masked by coiled-coil formation between LZ1 and LZ2 (Brock et al., 2005) . Finally, we added a peptide linker (L4) to the N termini to generate the tags L4-LZ1-KKXX and L4-LZ2-KKXX (hereafter, C1 and C2, respectively). The L4 peptide linker was composed of four repeats of amino acids EAAAK, which will generate a rigid a-helical rod (Arai et al., 2004) . Fusing C1 and C2 to the intracellular C termini of GluN2 subunits should allow selective surface expression of NMDA receptors composed of two GluN1, one C1-tagged GluN2, and one C2-tagged GluN2 ( Figure 1B ). To avoid potential incompatibility between trafficking signals present in GluN2A and GluN2B CTDs and between CTD structures and spatial requirements for the C1/C2 interaction, we replaced the CTD of GluN2B with that of GluN2A ( Figure 1A ). The functional properties of GluN2B subunits containing the CTD of GluN2A are indistinguishable from those of wild-type GluN2B (Maki et al., 2012; Punnakkal et al., 2012) . Thus, we generated C1-and C2-tagged GluN2A and GluN2B subunits (2A C1 , 2A C2 , 2B AC1 , and 2B AC2 ) that only differ in the intracellular CTDs by the leucine zipper motifs (LZ1 and LZ2). The amino acid sequences for the C1 and C2 peptide tags are shown in Figure S1 .
Coexpression of 2A C1 and 2B AC2 (as well as GluN1) in Xenopus oocytes produced robust current responses activated by glutamate plus glycine that increased in amplitude on days 1-3, following cRNA injection, and remained constant on days 4-6 ( Figures 1C and 1D ). In theory, the glutamate/glycine-activated currents from oocytes coexpressing 2A C1 , 2B AC2 , and GluN1 are mediated by NMDA receptors composed of one 2A C1 and one 2B AC2 with masked retention signals, as well as two GluN1 subunits (hereafter, 2A C1 /2B AC2 ). However, some 2A C1 /2A C1 and 2B AC2 /2B AC2 receptors that may have escaped ER retention could also contribute to the measured current responses. To evaluate the fraction of the total current response that is mediated by escaped receptors (i.e., ''escape'' current), we generated 2A C1 and 2B AC2 subunits with mutations in the agonist binding pocket that abolish glutamate binding (R518K + T690I in 2A C1(RK+TI) and R519K + T691I in 2B AC2(RK+TI) ) (Erreger et al., 2007; Hatton and Paoletti, 2005; Laube et al., 1997) . Coexpression of 2A C1 and 2B AC2(RK+TI) produces only one population of receptors that can be activated by 100 mM glutamate, namely, escaped 2A C1 /2A C1 , because agonist occupancy at two GluN2 subunits are required for NMDA receptor activation (Benveniste and Mayer, 1991; Clements and Westbrook, 1991) (Figures 1C  and 1D (Figures 1C and 1D ). The sum of the fractional currents from escaped 2A C1 /2A C1 and 2B AC2 /2B AC2 assessed using this approach will provide an estimate of the percent ''escape'' current in oocytes coexpressing 2A C1 and 2B AC2 that is mediated by receptors other than triheteromeric 2A C1 /2B AC2 . For the 2A C1 /2B AC2 subunit combination, the percent ''escape'' current was between 3%-7% on days 2-4 of expression (five batches of oocytes, n = 6 oocytes each day for each batch) (Figure 1E) . Similar results were obtained for 2A C1 /2A C2 and 2B AC1 / 2B AC2 subunit combinations ( Figure 1E ; see also Figure S1 ).
To provide an alternative evaluation of the efficiency by which the engineered peptide tags express a homogenous population of triheteromeric receptors, we introduced a mutation in the agonist binding pocket that reduces glutamate potency (H485A in GluN2A and H486A in GluN2B) (Anson et al., 1998; Hansen et al., 2005) . If there is observable ''escape'' current, then glutamate concentration-response data from oocytes coexpressing wild-type and mutated subunits will have three components mediated by receptors with one binding site mutated as well as escaped wild-type and double mutant receptors. Thus, this approach will allow evaluation of an ''escape'' current in individual oocytes by assessing the fractional sizes of the components in the glutamate concentration-response data (see Figures S2 and S3; Table S1 ). The results obtained using this approach to evaluate the efficiency of the peptide tags were consistent with ''escape'' currents estimated using the ''RK+TI'' mutations.
In summary, we have engineered peptide tags (C1 and C2) that upon fusion to the C terminus of GluN2A and GluN2B subunits facilitate selective expression of NMDA receptors with a defined subunit combination at the cell-surface, thereby enabling experiments on a homogenous population of triheteromeric GluN1/GluN2A/GluN2B receptors.
Inhibition of Triheteromeric Receptors by GluN2A-Selective Modulators
The lack of information regarding properties of triheteromeric receptors has been a major obstacle in studies using subtypeselective antagonists to assess the physiological roles of native NMDA receptors. Moreover, the inability to study triheteromeric NMDA receptors that are abundant in the adult brain complicates clinical development of subunit-selective modulators. By controlling the subunit composition of cell-surface-expressed receptors using the engineered peptide tags, we can begin to Neuron Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors quantitatively evaluate the activity of subunit-selective modulators at GluN1/GluN2A/GluN2B triheteromers.
We examined the GluN2A-selective antagonist TCN-201, which is a negative allosteric modulator of glycine binding to GluN1 (Bettini et al., 2010; Hansen et al., 2012) . The presence of the peptide tags in the CTD did not alter potency and maximal inhibition for TCN-201 at 2A C1 /2A C2 compared to wild-type 2A/ 2A, and TCN-201 did not display any activity at wild-type 2B/ 2B and 2B AC1 /2B AC2 receptors ( Figure 2A ; Table 1 ). However, the IC 50 of TCN-201 increased from 370 ± 30 nM at wild-type , and the re-entrant pore loop (M2) of GluN2A, GluN2B, GluN2A with C1-or C2-tags fused to the intracellular C terminus (2A CX ), and chimeric GluN2B subunits with the C-terminal domain replaced by that of C1-or C2-tagged GluN2A (2B ACX ). (B) Coexpression of GluN1 (omitted from cartoon for clarity) with two different GluN2 subunits in heterologous systems would normally generate three populations of functional NMDA receptors. However, fusing the C1 and C2 tags to the intracellular C-termini of GluN2 subunits should not allow cell-surface expression of receptors that contain two C1-tagged or two C2-tagged GluN2 subunits. (C) Representative two-electrode voltage-clamp recordings of responses from recombinant NMDA receptors expressed in Xenopus oocytes activated by 100 mM glutamate plus 50 mM glycine. GluN1 was coexpressed with 2A C1 and mutated 2B AC2 (R519K + T691I in 2B AC2(RK+TI) ), mutated 2A C1 (R518K + T690I in 2A C1(RK+TI) ) and 2B AC2 , or 2A C1 and 2B AC2 . The RK+TI mutations abolish binding of glutamate and render any NMDA receptor containing this subunit nonfunctional. (D) Coexpression of 2A C1 and 2B AC2 (as well as GluN1) produced robust currents responses that increased following cRNA injection (black), whereas current responses from 2A C1 /2A C1 and 2B AC2 /2B AC2 receptors that may have escaped ER retention remained small. Data are mean ± SEM, and each data point is from five batches of oocytes with six oocytes for each batch (n = 30). (E) The sum of the fractional currents assessed using the RK+TI mutations provided an estimate of the percent ''escape'' current in oocytes coexpressing 2A C1 and 2B AC2 , 2A C1 and 2A C2 , or 2B AC1 and 2B AC2 . See also Figures S1-S3 and Table S1 .
Neuron
Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors 2A/2A (n = 8) to 1,350 ± 130 nM at 2A C1 /2B AC2 triheteromers (n = 10) and maximal inhibition was reduced from 91% ± 1% to 72% ± 4% ( Figure 2A ; Table 1 ). Thus, the presence of a single GluN2A subunit in triheteromers reduces TCN-201 inhibition compared to receptors with two GluN2A subunits. TCN-201 inhibition of 2A C1 /2B AC2 and 2A C2 /2B AC1 triheteromers (i.e., the C1-and C2-tags were swapped between the GluN2A and GluN2B subunits) was not significantly different ( Figure S4 ).
Extracellular Zn
2+ can inhibit NMDA receptors at low nanomolar concentrations in a voltage-independent manner by binding to a high-affinity site in the amino-terminal domain (ATD) of GluN2A (Choi and Lipton, 1999; Paoletti et al., 2000) . In addition, Zn 2+ inhibition can occur through binding to the GluN2B ATD, albeit at higher micromolar concentrations (Karakas et al., 2009; Rachline et al., 2005) . Extracellular Zn 2+ can also produce a nonspecific voltage-dependent channel block through binding Table 1 and Figure S4 .
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Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors to the NMDA receptor ion channel pore (Williams, 1996) . Despite a significant role of Zn 2+ as an endogenous NMDA receptor modulator (Nozaki et al., 2011; Sensi et al., 2011) , little is known about its actions on GluN1/GluN2A/GluN2B triheteromers. One previous study reported inhibition of triheteromers by extracellular Zn 2+ in the nanomolar range but could not provide robust values for potency and efficacy (Hatton and Paoletti, 2005) . Because inhibition by extracellular Zn 2+ is considered relevant for the physiological function of GluN2A-containing NMDA receptors (Sensi et al., 2011) , we decided to determine the potency and efficacy at triheteromers. To minimize the voltage-dependent, low-affinity component of Zn 2+ inhibition, we recorded at a holding potential of À20 mV and Zn 2+ concentrations were kept below 300 nM. Under these conditions, we did not observe differences between Zn 2+ inhibition of wild-type 2A/2A and 2A C1 / 2A C2 , as well as wild-type 2B/2B and 2B AC1 /2B AC2 , supporting the idea that neither the GluN2A CTD in GluN2B nor the peptide tags change receptor properties ( Figure 2B ; Table 1 ). At physiological pH 7.3, Zn 2+ displayed high-potency inhibition of wild-type 2A/2A with an IC 50 value of 61 ± 4 nM and a maximal inhibition of 57% ± 2% (n = 18), consistent with previous reports (Low et al., 2000; Paoletti et al., 1997; Traynelis et al., 1998; Williams, 1996) . At a concentration of 265 nM, extracellular Zn 2+ reduced responses from wild-type 2B/2B to 80% ± 1% (n = 6) of control ( Figure 2B ; Table 1 ), consistent with minimal voltage-dependent channel block and inhibition primarily mediated through binding to the GluN2B ATD (Karakas et al., 2009; Rachline et al., 2005; Traynelis et al., 1998 was not significantly different ( Figure S4 ). The high-potency and efficacious inhibition of triheteromers by extracellular Zn 2+ was unexpected and suggest that not only GluN1/GluN2A diheteromers but also GluN1/GluN2A/GluN2B triheteromers in the adult brain are modulated by endogenous Zn 2+ .
Binding of Zn
2+ to the GluN2A ATD increases proton inhibition of the NMDA receptor, and Zn 2+ binding presumably inhibits the receptor by increasing proton affinity and thereby the fraction of protonated, nonfunctional receptors (Choi and Lipton, 1999; Traynelis, 2005, 2008; Low et al., 2000) . The functional link between Zn 2+ and proton inhibition causes the maximal Zn 2+ inhibition to increase at more acidic pH and diminish at more alkaline pH. We therefore compared Zn 2+ inhibition of 2A C1 /2B AC2 triheteromers and wild-type 2A/2A at a more alkaline pH of 7.8 and a more acidic pH of 6.8 (Figures 2C and 2E values of 62 ± 4 nM (n = 10) and 63 ± 7 nM (n = 10), respectively, and maximal inhibition of 29% ± 1% and 30% ± 1%, respectively. By contrast, there were differences between Zn 2+ inhibition of wild-type 2A/2A and 2A C1 / 2B AC2 triheteromers at acidic pH 6.8 with IC 50 values of 47 ± 2 nM (n = 6) and 57 ± 5 nM (n = 10), respectively, and maximal inhibition of 93% ± 2% and 65% ± 1%, respectively. These results suggest that although Zn 2+ binds with high affinity to NMDA receptors with a single GluN2A subunit, binding to a single site in the receptor is not capable of increasing proton inhibition to the same extent as binding to two high-affinity sites as in wild-type 2A/2A.
To values of 58 ± 2 nM (n = 28) and 44 ± 8 nM (n = 6), respectively, and maximal inhibition of 49% ± 1% and 47% ± 3%, respectively ( Figure 2H ). Because Zn 2+ binding to GluN2B Figure 2H ). The results obtained for GluN1/GluN2A diheteromers with a single or both Zn 2+ binding sites mutated are consistent with previous reports (Hatton and Paoletti, 2005; Nozaki et al., 2011; Paoletti et al., 2000) . However, the similar Zn 2+ inhibition of GluN1/ GluN2A/GluN2B triheteromers and GluN1/GluN2A diheteromers is unexpected when contrasted with the reduced Zn 2+ inhibition of 2A C1 /2A C1(H128S) and invites additional experiments to fully delineate the mechanism of Zn 2+ modulation.
Inhibition of Triheteromeric Receptors by GluN2B-Selective Modulators
Noncompetitive antagonists that selectively bind at the interface between GluN1 and GluN2B ATDs (Burger et al., 2012; Karakas et al., 2011) , such as ifenprodil and CP-101,606, have been extensively explored in the treatment of several neuropathological conditions (Traynelis et al., 2010) . Recently, these antagonists have received renewed interest following the discovery that CP-101,606 is effective against treatment-resistant depression (Preskorn et al., 2008) . Despite the considerable resources used in the development of GluN2B-selective antagonists as therapeutic agents, there is a problematic lack of information regarding the activity of these ligands at GluN1/GluN2A/GluN2B triheteromers.
We therefore compared ifenprodil inhibition of triheteromers to that of GluN1/GluN2A and GluN1/GluN2B diheteromers. We recorded at a holding potential of À40 mV to minimize nonspecific voltage-dependent inhibition by ifenprodil, which is pronounced at concentrations above 3 mM ( Figure S5 ). Ifenprodil reduced current responses from wild-type 2B/2B with an IC 50 of 72 ± 8 nM and maximal inhibition of 88% ± 2% (n = 8), whereas responses from wild-type 2A/2A were insensitive to 3 mM ifenprodil (n = 10) (Figures 3A and 3B ; Table 1 ). Ifenprodil inhibition of 2A C1 /2B AC2 triheteromers was markedly reduced compared to wild-type 2B/2B, because IC 50 increased 6.3-fold to 450 ± 30 nM and maximal inhibition was 32% ± 1% (n = 16). Ifenprodil inhibition of 2A C1 /2B AC2 and 2A C2 /2B AC1 triheteromers (i.e., the C1-and C2-tags were swapped) was not significantly different ( Figure S4) . Thus, the reduced ifenprodil inhibition of triheteromers compared to wild-type 2B/2B is in stark contrast to the virtually unchanged Zn 2+ inhibition of triheteromers compared to wild-type 2A/2A (Table 1) . Studies have suggested two populations of ifenprodil-sensitive NMDA receptors in the adult rodent forebrain that have been attributed to GluN1/ GluN2B diheteromers with high sensitivity and GluN1/GluN2A/ GluN2B triheteromers with lower sensitivity (Gray et al., 2011; Kew et al., 1998; Tovar and Westbrook, 1999) . Our ability to quantitatively evaluate the pharmacology of triheteromers conclusively validates this idea and also demonstrates that reduced ifenprodil sensitivity of triheteromers is mainly mediated by a diminished maximal inhibition rather than by a dramatic reduction in potency (Figures 3A and 3B ; Table 1 ).
To assess whether our findings regarding ifenprodil inhibition of triheteromers can transfer to other GluN2B-selective antagonists, we also evaluated CP-101,606. Responses from wild-type 2B/2B was inhibited by CP-101,606 with an IC 50 of 61 ± 3 nM and maximal inhibition of 89% ± 1% (n = 8), whereas responses from wild-type 2A/2A were insensitive to 3 mM CP-101,606 (n = 10) ( Figure 3C ; Table 1 ). CP-101,606 inhibition of 2A C1 /2B AC2 triheteromers had a maximal inhibition of 29% ± 2% and an IC 50 of 220 ± 20 nM (n = 9), which is increased 3.6-fold compared to wild-type 2B/2B. Thus, the presence of a single GluN2B subunit in 2A C1 /2B AC2 triheteromers has a quantitatively similar outcome for inhibition by ifenprodil and CP-101,606 ( Figures  3B and 3C ; Table 1) .
It has been shown previously that inhibition of triheteromers by a high concentration of ifenprodil is enhanced by the presence of extracellular Zn 2+ , presumably through Zn 2+ binding to the single high-affinity site in the GluN2A ATD (Hatton and Paoletti, 2005) .
To study this observation in more detail, we generated ifenprodil and CP-101,606 concentration-response data in the presence of 300 nM Zn 2+ . The presence of extracellular Zn 2+ resulted in a slight increase in both ifenprodil and CP-101,606 potencies at wild-type 2B/2B without affecting maximal inhibition ( Figures  3D and 3E ; Table 1 ), whereas wild-type 2A/2A remained insensitive to both ifenprodil (n = 10) and CP-101,606 (n = 10). Ifenprodil and CP-101,606 potencies were slightly increased at 2A C1 / 2B AC2 triheteromers by the presence of extracellular Zn 2+ , whereas a more pronounced effect on maximal inhibition could be observed. Maximal ifenprodil inhibition increased from 32% ± 1% (n = 16) in the absence of Zn 2+ to 50% ± 2% (n = 8) in the presence of Zn 2+ , and maximal CP-101,606 inhibition increased from 29% ± 2% (n = 9) to 58% ± 2% (n = 8) ( Figures  3D and 3E ; Table 1 ). This finding is highly relevant to the application of GluN2B-selective antagonists as pharmacological tools or therapeutic agents, because tonic or synaptic Zn 2+ have been suggested to be present during electrophysiological recordings and in normal brain physiology (Paoletti et al., 1997; Sensi et al., 2011; Traynelis et al., 1998) .
Time Course of Ifenprodil Inhibition of GluN1/GluN2A/ GluN2B Receptors In order to investigate the nature of the ifenprodil binding site in GluN1/GluN2A/GluN2B triheteromers, we evaluated the kinetics of ifenprodil inhibition using fast-application whole-cell patchclamp recordings. For this purpose, we first optimized the engineered peptide tags to control subunit composition of NMDA receptors expressed in HEK293 cells (see the Experimental Procedures). Initially, we measured the time course and concentration-dependence of ifenprodil inhibition of steady-state responses from wild-type 2B/2B ( Figure 4A ). The onset of ifenprodil inhibition of wild-type 2B/2B was adequately described by a single exponential function to obtain the inhibition time
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Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors constants (t inhibition ). Furthermore, 1/t inhibition was linearly related to the concentration of ifenprodil ( Figure 4C ), which is consistent with a simple bimolecular reaction. The slope of the linear fit to this relationship therefore provides the rate of ifenprodil binding (k on ), which was 0.263 mM À1 ,s À1 for wild-type 2B/2B (95% confidence interval was 0.236-0.290 mM
À1
,s À1 ; n = 6). Assuming that unbinding is concentration-independent, the rate of ifenprodil unbinding (k off ) derived from the y intercept was 0.096 s À1 (95% confidence interval was 0.051-0.141 s À1 ).
Thus, the K d = k off /k on for ifenprodil binding to wild-type 2B/2B was 370 nM, which is similar to the K d of 320 nM measured using isothermal titration calorimetry with purified GluN1 and GluN2B ATDs (Karakas et al., 2011).
We next measured the kinetics of ifenprodil inhibition of steady-state responses from 2A C1 /2B AC2 triheteromers (Figure 4B) . Again, the onset of ifenprodil inhibition could be described by a single exponential function, and 1/t inhibition was linearly related to the concentration of ifenprodil ( Figure 4C ). See also 
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Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors in HEK293 cells expressing 2A C1 /2B AC2 triheteromers, the kinetics of ifenprodil inhibition are clearly distinct from those of wild-type 2B/2B. In addition, the inhibition by 2.5 mM ifenprodil was 36% ± 1% (n = 6) in HEK293 cells expressing 2A C1 /2B AC2 triheteromers, which is similar to the maximal inhibition observed in Xenopus oocytes (32% ± 1%; Table 1 ). The findings that ifenprodil has a markedly slower rate of inhibition, as well as reduced binding affinity and efficacy at GluN1/GluN2A/GluN2B triheteromers, compared to GluN1/GluN2B diheteromers suggest structural variation between the ifenprodil binding sites of triheteromeric and diheteromeric GluN2B-containing NMDA receptors.
Deactivation Time Course for GluN1/GluN2A/GluN2B Receptors GluN2A and GluN2B subunits play distinct physiological roles in many processes of the central nervous system (Paoletti et al., 2013) . GluN2B is highly expressed early in development, whereas expression of GluN2A increases during development (Sanz-Clemente et al., 2013) . This developmental shift in the relative expression level of these subunits is accompanied by a profound change in pharmacological and functional properties of NMDA receptors. One prominent functional difference is the deactivation time course, which defines the time course of the excitatory postsynaptic current (Lester et al., 1990) . The time course of deactivation is in the tens-of-millisecond range for GluN1/GluN2A diheteromers and in the hundreds-of-millisecond range for GluN1/GluN2B . However, the deactivation kinetics of NMDA receptor EPSCs in hippocampal and cortical neurons from adult rodents cannot be explained by a mixture of GluN1/GluN2A and GluN1/GluN2B diheteromers, suggesting that GluN1/GluN2A/GluN2B triheteromers exist in these neurons with distinct and intermediate deactivation kinetics (Gray et al., 2011; Rauner and Kö hr, 2011; Tovar et al., 2013) . We directly measured the deactivation time course following removal of glutamate for triheteromeric and diheteromeric NMDA receptors expressed in HEK293 cells using 
Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors fast-application whole-cell patch-clamp recordings. Initially, we compared the deactivation kinetics following brief (5 ms) pulses of a supersaturating concentration of glutamate (1 mM) in the continuous presence of glycine (100 mM). For all receptors, the deactivation time course was adequately described by a double exponential function to obtain time constants for fast and slow components (t fast and t slow ), and the weighted time constant (t weighted ) could be calculated using the relative contribution from each of these components (Table 2) . Consistent with the concentration-response data, neither the presence of the peptide tags nor the GluN2A CTD in GluN2B changed receptor function, because t weighted was not significantly different between wild-type 2A/2A and 2A C1 /2A C2 , or between wild-type 2B/2B and 2B AC1 /2B AC2 (unpaired t test; two-tailed, p > 0.05) ( Table  2 ). The t weighted for glutamate deactivation of wild-type 2A/2A (32 ± 1 ms; n = 11) was approximately 10-fold smaller than the corresponding t weighted of wild-type 2B/2B (314 ± 13 ms; n = 15) (Figures 4D and 4E ; Table 2 ). For 2A C1 /2B AC2 triheteromers, t weighted was 57 ± 4 ms (n = 17), which is significantly different from t weighted values of both wild-type 2A/2A and 2B/2B (unpaired t test; two-tailed, p < 0.05) (Figures 4D and 4E ; Table 2 ). Similar results were obtained for all subunit combinations following longer glutamate application (2 s) ( Figure S6 ; Table S2) . Thus, we demonstrate that the presence of a single GluN2A results in a striking acceleration of glutamate deactivation that endows GluN1/GluN2A/GluN2B triheteromers with a distinct and intermediate deactivation time course compared to both GluN1/GluN2A and GluN1/GluN2B diheteromers. In addition to reducing the response amplitude, it has been demonstrated that binding of extracellular Zn 2+ to GluN2A or ifenprodil to GluN2B is accompanied by a deceleration of the deactivation kinetics for GluN1/GluN2A or GluN1/GluN2B diheteromers, respectively (Bhatt et al., 2013; Erreger and Traynelis, 2005; Kew et al., 1996; Paoletti et al., 1997; Tovar and Westbrook, 2012) . The change in the kinetics of glutamate responses mediated by modulators can modify the temporal characteristics of synaptic integration, which could have physiological and therapeutic relevance. In order to examine the effects of extracellular Zn 2+ and ifenprodil on the deactivation kinetics, we compared responses to brief (5 ms) glutamate applications in absence of antagonists (control) to responses in the continuous presence of either 1 mM ifenprodil or 300 nM extracellular Zn
2+
obtained from the same cell (i.e., paired recordings). The continuous presence of extracellular Zn 2+ significantly increased t weighted of wild-type 2A/2A from 33 ± 1 ms (control) to 55 ± 2 ms (n = 6; paired t test; two-tailed; p < 0.05), whereas ifenprodil did not change the deactivation time course of wild-type 2A/2A (Figures 5A and 5C ; Table 2 ). Inhibition of peak responses by extracellular Zn 2+ or ifenprodil is shown in Figure 5B . For wildtype 2B/2B, ifenprodil significantly increased t weighted from 327 ± 17 ms (control) to 490 ± 33 ms (n = 6; paired t test; twotailed; p < 0.05), whereas extracellular Zn 2+ had no effect on the deactivation time course (Figures 5A and 5E ; Table 2 ). Both in the case of extracellular Zn 2+ action on wild-type 2A/2A and ifenprodil action on wild-type 2B/2B, the slower deactivation time course is mediated by an increase in the time constant for the slow component (t slow ) without noticeable changes in the time constant and relative contribution of the fast component (t fast and % fast) ( Table 2) .
The presence of ifenprodil resulted in a small, but significant, increase in t weighted of 2A C1 /2B AC2 triheteromers from 55 ± 3 ms (control) to 60 ± 4 ms (n = 6; paired t test; two-tailed; p < 0.05), whereas extracellular Zn 2+ produced a more pronounced increase to 88 ± 5 ms (p < 0.05) (Figures 5A and 5D ; Table 2 ). Both extracellular Zn 2+ and ifenprodil slowed the deactivation time course of 2A C1 /2B AC2 triheteromers mainly by increasing the relative contribution of the slow component without changing the time constant of the fast component (t fast ) (Table 2) . Thus, the presence of a single GluN2A in the triheteromer has a strong effect on both the glutamate deactivation time course and the capacity of subunit-selective ligands to robustly modify this time course.
DISCUSSION
Despite the widespread interest in NMDA receptors as therapeutic targets, it has not been possible to describe the functional or pharmacological properties of triheteromeric NMDA receptors that are abundantly expressed in the CNS. The main issue preventing discoveries on this front has been related to the problem of expressing a homogenous population of triheteromeric . Deactivation time courses were described using dual-exponential fits to obtain t fast and t slow , and % fast is the fitted percentage of the fast component. Weighted time constants (t weighted ) were calculated as described in Table S2 . Control t weighted were compared using an unpaired t test (two-tailed). Control t weighted were also compared to t weighted obtained in the presence of ifenprodil or extracellular Zn 2+ for the same cell using a paired t test (two-tailed). n is the number of cells and all values are mean ± SEM. See also Figure S6 and Table S2 
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Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors receptors in heterologous expression systems. Here, we describe an approach to overcome this obstacle and reveal features of GluN1/GluN2A/GluN2B triheteromers that can have implications for their role in synaptic transmission and for drug discovery. We estimate that the approach to selectively express GluN1/GluN2A/GluN2B triheteromers at the cell surface using engineered C-terminal peptide tags is highly efficient with <10% of the total current response mediated by GluN1/GluN2A and GluN1/GluN2B diheteromers. Furthermore, our results demonstrate that the presence of engineered C-terminal peptide tags on GluN2 subunits does not modify NMDA receptor function or pharmacology, thereby enabling stronger conclusions to be drawn from kinetic and mechanistic studies. GluN1/ GluN2A/GluN2B is the major subtype in hippocampus and cortex of the adult rodent brain (Al-Hallaq et al., 2007; Luo et al., 1997; Rauner and Kö hr, 2011; Sheng et al., 1994; Tovar et al., 2013) , but other triheteromeric NMDA receptors subtypes have also been identified in the CNS. GluN1/GluN2B/GluN2D is expressed in cerebellar Golgi cells (Brickley et al., 2003) , hippocampal granule cells (Piñ a-Crespo and Gibb, 2002) , and substantia nigra (Jones and Gibb, 2005) , whereas GluN1/GluN2A/ GluN2C is found in adult cerebellar granule cells (Cathala et al., 2000; Chazot et al., 1994) . The approach using engineered peptide tags could potentially enable studies on these other, virtually unexplored, triheteromeric subtypes in heterologous expression systems. However, given the marked diversity in sequence, length, and function of the GluN2 CTDs, as well as in the greatly varying open probability determined by the GluN2 subunits (Paoletti et al., 2013; Sanz-Clemente et al., 2013; Traynelis et al., 2010) , it would likely require optimization of the C-terminal peptide tags and of the expression system to ensure that only triheteromeric receptors are functionally expressed at the cell surface. We demonstrate a remarkably fast glutamate deactivation of GluN1/GluN2A/GluN2B triheteromers with a time constant that is 1.8-fold slower than that of GluN1/GluN2A diheteromers but 5.5-fold faster than that of GluN1/GluN2B diheteromers. This acceleration mediated by the GluN2A subunit is comparable to changes observed for NMDA receptor-mediated excitatory postsynaptic currents (EPSCs) in developing hippocampal and cortical neurons as GluN2A expression increases with age (Flint et al., 1997; Gray et al., 2011; Kirson and Yaari, 1996; Stocca and Vicini, 1998) . The strong effect of GluN2A on glutamate deactivation mirrors the pharmacology, because extracellular Zn 2+ inhibits GluN1/GluN2A/GluN2B triheteromers and GluN1/GluN2A diheteromers with similar potency and efficacy in a manner that appears independent of the GluN2B subunit. By contrast, both potency and efficacy of GluN2B-selective antagonists 606) are markedly reduced at GluN1/ GluN2A/GluN2B triheteromers compared to GluN1/GluN2B diheteromers. Extracellular Zn 2+ also mediates a more pronounced deceleration of glutamate deactivation of triheteromers compared to ifenprodil. The asymmetrical outcome of Zn 2+ and ifenprodil binding on deactivation of triheteromers nicely obtained from the same cell (i.e., paired recordings). Asterisk denotes significantly different (paired t test; two-tailed, p < 0.05). ns, not significant. See also Table 2 .
Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors matches effects on NMDA receptor-mediated EPSCs from cultured hippocampal neurons suggested to predominantly express GluN1/GluN2A/GluN2B triheteromers (Tovar et al., 2013; Tovar and Westbrook, 2012) . The striking similarities between GluN1/GluN2A/GluN2B triheteromers and GluN1/ GluN2A diheteromers with respect to both function and pharmacology could render these subtypes indistinguishable under some experimental conditions and raises the possibility that the contribution of GluN1/GluN2A diheteromers to synaptic physiology is overestimated in some studies. GluN2A and GluN2B subunits interact with different complements of intracellular proteins, including scaffolding proteins, and their trafficking is differentially regulated in neurons (SanzClemente et al., 2013; Traynelis et al., 2010 ). GluN2A appears to preferentially reside in synapses, whereas GluN2B can be found both at synaptic and extrasynaptic sites (Bard and Groc, 2011) . In addition, it has been elegantly demonstrated that GluN2B possesses endocytotic and recycling motifs in the CTD that dominate sorting of triheteromeric GluN1/GluN2A/ GluN2B receptors; a finding that is supported by the observation that GluN2B trafficking is unaffected by the absence of GluN2A expression in GluN2A knockout mice (Tang et al., 2010) . The GluN2A-dependent acceleration of EPSCs that occurs during development has profound effects on the temporal signaling properties and charge transfer, both of which have important consequences for synaptic plasticity. Thus, any triheteromeric NMDA receptor subtype is likely endowed with a unique combination of trafficking and functional properties tailored to meet the requirements at a specific subcellular location or a specific population of cells in the CNS.
The strong influence of GluN2A on glutamate deactivation and pharmacology of GluN1/GluN2A/GluN2B triheteromers suggests asymmetrical contributions of GluN2A and GluN2B to long-range allosteric interactions and conformational states of the receptor. This idea is supported by the significant reduction of the ifenprodil binding rate to triheteromers compared to GluN1/GluN2B diheteromers. Our interpretation of this result is that the GluN2A subunit of GluN1/GluN2A/GluN2B triheteromers influences the ifenprodil binding pocket at the interface between ATDs of GluN1 and GluN2B. This would imply that the orientation or dynamics of the ATDs is different in GluN1/GluN2A/GluN2B triheteromers compared to GluN1/GluN2B diheteromers. The possibility of variation between ifenprodil binding pockets of triheteromers and GluN1/GluN2B diheteromers has important implications for drug discovery, because this difference could be exploited for the development of a new generation of therapeutic agents that selectively target GluN1/GluN2A/GluN2B triheteromers.
In summary, we have provided comprehensive assessment of properties relevant for synaptic signaling and therapeutic manipulation of what may be the most abundant NMDA receptor subtype in the adult hippocampus and cortex. In doing this, we developed an approach to study triheteromeric NMDA receptors and revealed distinct functional and pharmacological features of GluN1/GluN2A/GluN2B triheteromeric receptors. In the past decade, the focus on triheteromeric NMDA receptors has increased significantly as a growing body of biochemical and anatomical studies has identified triheteromers in most regions of the CNS. The approach and the results described in the present study fill a critical gap in our understanding of glutamate receptors and pave the way for future studies to investigate the role of different triheteromeric NMDA receptor subtypes in normal brain function and disease.
EXPERIMENTAL PROCEDURES

DNA Constructs and Ligands
Rat cDNAs for GluN1-1a (GenBank accession number U08261; hereafter, GluN1), GluN2A (D13211), and GluN2B (U11419) were provided by Drs. S. Heinemann (Salk Institute) and S. Nakanishi (Osaka Bioscience Institute). The cDNA encoding rat GluN2B was modified without changing the amino acid sequence to remove a T7 RNA polymerase termination site located immediately following transmembrane helix M4 (see the Supplemental Experimental Procedures). The cDNAs encoding the peptide tags C1 and C2 were custom synthesized (Genscript) and inserted in place of the stop codon in the open reading frame of GluN2A to generate 2A C1 and 2A C2 ( Figure S1 ). The CTD of the GluN2B subunit was then replaced by the CTD of the GluN2A subunits 2A C1 and 2A C2 . Residues 1-844 of resulting chimeric subunits, denoted 2B AC1 and 2B AC2 , were identical to GluN2B, and the remaining residues were identical to residues 844-1541 and 844-1533 from 2A C1 and 2A C2 , respectively. All GluN2 cDNAs were inserted into the pCI-neo vector (Promega). The pCI-neo vector was used to express GluN1 in Xenopus oocytes, whereas the GluN1 cDNA was under the control of the inducible promoter in the pTRE-tight vector for expression in HEK293 Tet-On Advanced cells (Clontech). In addition, cDNA encoding EGFP was inserted between the inducible promoter and the open reading frame of GluN1 (EGFP and GluN1 were not expressed as a fusion protein) in order to reduce expression of GluN1 and obtain a linear relationship between EGFP and GluN1 expression. Amino acids are numbered according to full-length protein, including the signal peptide. See the Supplemental Experimental Procedures for full details.
Two-Electrode Voltage-Clamp Recordings
Preparation and injection of Xenopus oocytes were performed essentially as previously described (Hansen et al., 2013) . For experiments using tagged GluN2 subunits, the cRNAs encoding GluN1, as well as C1-and C2-tagged GluN2, were injected at a 1:6:6 ratio at a total volume of 50 nl. For all experiments, the cRNA was diluted with RNase-free water to a concentration that would result in $10 ng of total injected cRNA. See the Supplemental Experimental Procedures for full details.
Whole-Cell Patch-Clamp Recordings HEK293 Tet-On Advanced cells (Clontech) were transfected with plasmid cDNAs encoding GluN1 (together with EGFP in the pTRE-tight vector) and GluN2 subunits at a ratio of 1:2 using the calcium phosphate precipitation method as previously described (Hansen et al., 2013) . To minimize cytotoxicity, the culture medium was supplemented with NMDA receptor antagonists D,L-2-amino-5-phosphonovalerate (200 mM) and 7-chlorokynurenic acid (200 mM). In addition, 5 ng/ml doxycycline was added to the medium to induce low-level expression of GluN1. Experiments were performed approximately 24 hr following transfection. For experiments on triheteromeric receptors, it was important to only include cells with current responses less than 1,000 pA in order to minimize overexpression, which has the potential to circumvent the ER retention signals in the engineered peptide tags. Lower expression levels (i.e., current responses less than 1,000 pA) improved the ability of the cell to control trafficking and selectively express triheteromeric receptors at the cell surface. See the Supplemental Experimental Procedures for full details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, six figures, and two tables and can be found with this article online at http:// dx.doi.org/10.1016/j.neuron.2014.01.035.
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